United Kingdom Archives

Startup Scout 11 May 2018

This Oxford Biotech is Using DNA to Find New Peptide Drugs

Today, we’re in Oxford, UK, visiting Orbit Discovery. The biotech develops peptide drugs for chronic diseases using DNA to tag potential therapeutic proteins. Mission: Orbit Discovery develops peptide drugs for a range of conditions including metabolic, autoimmune and cardiovascular diseases using beads to connect peptides to the DNA that encodes them and see how well the peptides […]

May 11, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 3 May 2018

FDA Backs Gene Therapy for Fatal Neurodegenerative Childhood Disease

Orchard Therapeutics has received a fourth Rare Pediatric Disease Designation from the FDA for its gene therapy candidate for metachromatic leukodystrophy. Orchard Therapeutics, based in London, has received a Rare Pediatric Disease Designation form the FDA for its gene therapy OTL-200. The treatment is for patients with metachromatic leukodystrophy (MLD), a fatal genetic disease that causes […]

May 3, 2018 - 1 minutemin - By Alexander Burik

needle free blood sugar testing graphene patch

More News! 12 Apr 2018

Graphene Skin Patch Measures Blood Sugar Without a Needle

Researchers in the UK have developed a skin patch that measures blood sugar levels without the prick of a needle by pulling fluid out from between hair follicles. The technology could be used for both type 1 and type 2 diabetes patients. Diabetes is a major global health problem, with the World Health Organization stating 422 […]

April 12, 2018 - 2 minutesmins - By Alexander Burik

Oxford Nanopore Technologies Fundraising

News and Trends 20 Mar 2018

DNA Sequencing Unicorn Oxford Nanopore Raises £100M Round at £1.5Bn Valuation

Undeterred by competitors, Oxford Nanopore, one of the few unicorns in the biotech space, has secured £100M (€113M) to continue growing its unique next-generation sequencing platform. Oxford Nanopore is one of the best-funded biotechs in Europe, having raised £507.3M (€578M) in total, and famous for its “DNA-reading gadget the size of a Mars bar that sells for $1,000.” The company plans to […]

March 20, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 20 Mar 2018

Oxford Firm Develops Better Test for ALS Diagnosis

Oxford BioDynamics has presented data from a new diagnostic test that could help not just diagnose ALS but also help patients get a personalized treatment. Amyotrophic lateral sclerosis (ALS) is a motor neuron disease whose diagnosis comes with the hard news that most patients die merely within 3 to 5 years of diagnosis. One of […]

March 20, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 15 Mar 2018

New Antibiotic for MRSA Infections is Ready for US Clinical Trials

Update (15/03/2018): The FDA has granted Fast Track Designation to XF-73, an antibody being developed by Destiny Pharma against post-surgical MRSA infections. Originally published on 26/02/2018 Destiny Pharma’s antibiotic for post-surgical infections will begin its clinical development after the FDA accepted its Investigational New Drug application. Destiny Pharma wants to combat the growing antibiotic resistance […]

March 15, 2018 - 2 minutesmins - By Alex Dale

News and Trends 13 Mar 2018

This Oxford Spin-out Could be Printing New Body Parts

The Oxford spin-out OxSyBio has secured £10M (€11,26M) to develop a 3D tissue printer that uses liquid droplets to design and regenerate tissues. Founded in 2014, OxSyBio is developing a technology to 3D print living tissues in order to replace body parts that are damaged by disease or injury. The substantial Series A funding was provided by Woodford Investment […]

March 13, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 12 Mar 2018

A Flick of a Switch Can Cause Age-Related Brain Deterioration

Switching certain genes on or off causes the premature aging of stem cells that repair the brain. Identifying them could provide a target for new therapeutic approaches against neurodegenerative diseases. Scientists at the Babraham Insitute in Cambridge and the University of Sapienza in Rome have identified a number of genes involved in the aging of […]

March 12, 2018 - 3 minutesmins - By Alex Dale

News and Trends 6 Mar 2018

Oxford Spin-out Moves Gene Therapy For Blindness Into Phase III Trial

Nightstar Therapeutics will begin the first Phase III trial for a gene therapy targeting choroideremia, a rare disorder leading to complete blindness. Nightstar will launch the first-ever Phase III trial testing a gene therapy for choroideremia, a genetic disorder characterized by night blindness and gradual loss of vision that eventually leads to complete blindness. The trial, STAR, […]

March 6, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 28 Feb 2018

Now We Know How the Brain Controls Pain, Better Analgesia Should Be on the Way

Researchers at the University of Cambridge believe that they have found the region of the brain that is responsible for pain relief, which should help future drug development efforts. Scientists at the University of Cambridge have identified the area of the brain that is responsible for pain relief, which could boost the development of alternative […]

February 28, 2018 - 4 minutesmins - By Alex Dale

News and Trends 27 Feb 2018

This Small Molecule Protects the Muscles of Patients With Duchenne Muscular Dystrophy

Summit Therapeutics’ treatment for the devastating disease, Duchenne muscular dystrophy, reduces inflammation, which could protect muscle fibers from damage. Summit Therapeutics focuses on the development of treatments that can help patients suffering from diseases that currently lack options. The biotech has reported Phase II results for its drug for the genetic disease, Duchenne muscular dystrophy […]

February 27, 2018 - 3 minutesmins - By Alex Dale

News and Trends 26 Feb 2018

This Oral Vaccine for Typhoid Raises €8M from International Investors

Prokarium has raised $10M (€8M) from Saudi, Swedish and Korean investors to support the clinical development of its oral vaccines for infectious diseases like typhoid. Since its foundation in 2012, Prokarium has been working on oral vaccines and it has developed a delivery platform that can be applied to any antigen used for vaccination. The biotech has […]

February 26, 2018 - 3 minutesmins - By Alex Dale

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us